Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
about
HCV Kinetic Models and Their Implications in Drug DevelopmentPopulation pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Platelet Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal OxaliplatinPopulation pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.A mechanism-based pharmacokinetic/pharmacodynamic model for CYP3A1/2 induction by dexamethasone in ratsPopulation Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamicsInformative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjectsA pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.Pharmacokinetic-Pharmacodynamic Model for the Effect of l-Arginine on Endothelial Function in Patients with Moderately Severe Falciparum Malaria.Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents.Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression.Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.Predicting allopurinol response in patients with goutKinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis.Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary TuberculosisDevelopment of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patientsCyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics.Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy.
P2860
Q26801602-95BEC7E1-E5D7-4A95-8967-1096FBDA9BB3Q33380427-3B663574-43BE-4871-8F51-794EB9BBAFB3Q33383483-DC54F671-369D-47DC-8C44-A85FD4227F90Q33408198-C0FE1F7C-33DA-4174-B4E8-AFFDE0E06E86Q33415594-1D35CD53-F93D-4048-8BA2-45C18E62EF9EQ33427607-493494B7-CED4-42E3-9FA4-F27B215CE195Q33439246-EE46C76F-90F5-4586-8E07-6008587ED4BFQ33567046-5D6D1593-2597-488D-8118-6C81DE2D4925Q33581536-C5062227-9F82-4B53-8F77-A8FC80001D50Q33716001-ECB0A394-213A-4DA0-8E77-7C2519F701A7Q33729778-4A8A9CDD-CD87-44B7-BE35-2CC914205AEEQ33743151-C8E5DEF8-FE40-45B2-8D35-2F825AFADFD9Q33822458-41729FBB-85B6-43A1-9508-76DDDFB86678Q33824750-FD334B6C-59EC-45C6-8C0A-9B73C450AF3FQ34293586-D5C12F1C-3334-464A-A113-9E9ACCC90A0AQ34486811-0F37409A-ED16-4FD3-9960-01281690B5A4Q34580659-B6FA028F-7A36-49F9-8A21-904418A4D42FQ34860261-B0AAE9DE-7F4D-441C-8612-73B682E7DAB1Q34996927-B8842750-0034-41D1-9C12-574F6125430CQ35132886-30B15B2C-0C8D-46C6-99A8-A83ED7693EB4Q35449696-F8C2DD85-B856-4B61-92B0-4C9D87C33C7AQ35678145-11BEFC44-F7DF-402C-A9A0-52CC43985DA4Q35813576-237AD82F-601F-4B8A-A9C0-1F4904E2B203Q35826943-E44FFFA2-3B37-453C-A5D7-15F452D3E8E5Q35893890-97662A01-E6FB-48B6-8AB5-0B428B6545CCQ35960882-935E9277-6CF2-453B-B227-6B0C49E1EF9CQ36087946-5186F6AA-DB19-41CB-9DCF-2667DE03CA72Q36125978-93A58F3E-F569-4242-A820-FB536976380BQ36188725-8A7F1A5B-59BD-44C7-8D98-0E79DF2172ADQ36407822-E68FFACD-8263-4230-A48E-60BC23F9E378Q36618085-2DA3B4B9-BD5D-467A-B4BC-881C32257398Q36653951-A8FB5D46-4135-461C-9262-61E95898E255Q36802064-CFA41417-03BB-42B1-AEBD-D891D3EF999DQ36839978-37A3AE67-4A12-469E-B479-14AC702C3AB8Q36853534-7F199589-1E1E-4314-A65D-610BD041FD1EQ36918510-B82A00D4-259F-4581-8099-D2B6665F5752Q37030730-AA94CEE6-E43C-4885-B788-73AF3A772088Q37297410-239F01ED-9E50-4DDB-A939-73D5FA90BD62Q37361446-37694111-2056-4663-8C96-59F8F42EF611Q37385389-17BB0F33-D7B1-4C9D-99A4-11F42C33EE90
P2860
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@ast
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@en
type
label
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@ast
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@en
prefLabel
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@ast
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@en
P2093
P1476
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
@en
P2093
Lewis B Sheiner
Liping Zhang
Stuart L Beal
P304
P356
10.1023/B:JOPA.0000012998.04442.1F
P577
2003-12-01T00:00:00Z
P6179
1004439377